

# 1 **Prevalence of Venous Thromboembolism in Critically-ill COVID-19** 2 **Patients: Systematic Review and Meta-analysis**

3 Mouhand F.H. Mohamed, MD, M. Sc<sup>1</sup>, Shaikha D. Al-Shokri.MD<sup>1</sup>, Khaled M. Shunnar.  
4 MBBS<sup>1</sup>, Sara F. Mohamed. MBBS<sup>1</sup>, Mostafa S. Najim. MBBS<sup>1</sup>, Shahd I. Ibrahim<sup>1</sup>, Hazem  
5 Elewa. RPh, PhD, BCPS<sup>2</sup>, Khalid M. Dousa. MD<sup>3</sup>, Lina O. Abdalla. MBBS<sup>1</sup>, Ahmed El-  
6 Bardissy. Pharm D<sup>4</sup>, Mohamed Nabil Elshafei. PharmD<sup>4</sup>, Ibrahim Y. Abubeker. MD<sup>5</sup>  
7 Mohammed Danjuma. MBBS, M. Sc, PhD<sup>1,6</sup>, Mohamed A Yassin. MD, M. Sc<sup>7</sup>

8  
9 <sup>1</sup> Department of Medicine, Hamad Medical Corporation, Doha, Qatar.

10 <sup>2</sup> College of Pharmacy, QU Health, Qatar University, Doha, Qatar

11 <sup>3</sup> Division of Infectious Diseases & HIV Medicine, University Hospitals Cleveland Medical  
12 Center, Case Western Reserve University, Cleveland, Ohio, USA.

13 <sup>4</sup> Clinical Pharmacy Department. Hamad General Hospital, Doha, Qatar.

14 <sup>5</sup> Alpert Medical School, Brown University, Providence, Rhode Island, USA

15 <sup>6</sup> College of Medicine, QU Health, Qatar University, Doha, Qatar.

16 <sup>7</sup> Department of Hematology, Hamad Medical Corporation, Doha, Qatar.

17 **Short title:** Venous thromboembolism in Critical COVID-19 patients: Meta-analysis

## 18 **Correspondence**

19 Mouhand F.H. Mohamed, MD, M. Sc<sup>1</sup>, Internal Medicine Department, Hamad Medical  
20 Corporation, Doha, Qatar. PO Box: 3050, email: [dr.m.oraiby@hotmail.com](mailto:dr.m.oraiby@hotmail.com).

21 ORCID: 0000-0002-4761-8014

22  
23  
24  
25  
26  
27  
28

29

30 **Abstract**

31 Background: Recent studies revealed a high prevalence of venous thromboembolism (VTE)  
32 events in coronavirus disease 2019 (COVID-19) patients, especially in those who are critically  
33 ill. Available studies report varying prevalence rates. Hence, the exact prevalence remains  
34 uncertain. Moreover, there is an ongoing debate regarding the appropriate dosage of  
35 thromboprophylaxis. Methods: We performed a systematic review and proportion meta-analysis  
36 following PRISMA guidelines. We searched PubMed and EMBASE for studies exploring the  
37 prevalence of VTE in critically ill COVID-19 patients till 22/07/2020. We pooled the proportion  
38 of VTE. Additionally, in a subgroup analysis, we pooled VTE events detected by systematic  
39 screening. Finally, we compared the odds of VTE in patients on prophylactic compared to  
40 therapeutic anticoagulation. Results: The review comprised of 24 studies and over 2500 patients.  
41 The pooled proportion of VTE prevalence was 0.31 (95% CI 0.24, 0.39  $I^2$  94%), of VTE utilizing  
42 systematic screening was 0.48 (95% CI 0.33, 0.63  $I^2$  91%), of deep-venous-thrombosis was 0.23  
43 (95% CI 0.14, 0.32  $I^2$  96%), of pulmonary embolism was 0.14 (95% CI 0.09, 0.20  $I^2$  90%). In a  
44 subgroup of studies, utilizing systematic screening, VTE risk increased significantly with  
45 prophylactic, compared to therapeutic anticoagulation (OR 5.45; 95% CI 1.90, 15.57  $I^2$  0%).  
46 Discussion: Our review revealed a high prevalence of VTE in critically ill COVID-19 patients.  
47 Almost 50% of patients had VTE detected by systematic screening. Higher thromboprophylaxis  
48 dosages seem to reduce VTE burden in this patient's cohort compared to standard prophylactic  
49 anticoagulation; ongoing randomized controlled trials will further confirm this.

50 **Keywords:** COVID-19, SARS-CoV-2, VTE, thrombosis, venous, ICU, DVT

51

## 52 **Introduction**

53 The pool of recent evidence suggests that Coronavirus disease 2019 (COVID-19) is a  
54 thrombogenic condition. It leads to an increased incidence of both venous and arterial  
55 thromboembolic events.<sup>1</sup> COVID-19 patients admitted to intensive care units (ICU) seem to  
56 carry a higher risk.<sup>1</sup> Venous thromboembolism (VTE) prevalence in the critically ill COVID-19  
57 patients varied across individual studies. This is likely due to differences in screening methods  
58 (systematic vs. nonsystematic screening), among other study-specific characteristics, leaving  
59 VTE's exact prevalence unknown. The prevalence of deep venous thrombosis (DVT) was  
60 considered low compared to pulmonary embolism (PE), which led researchers to consider micro  
61 thrombosis as an additional mechanism of PE in COVID-19 patients.<sup>2</sup>

62 VTE's heightened risk led to a wide chemoprophylaxis use for critically ill COVID-19 patients<sup>3</sup>.  
63 Notwithstanding this, recent studies showed that even COVID-19 patients on chemoprophylaxis  
64 remain to carry a high risk of VTE compared to non-COVID-19 patients.<sup>4</sup> As a result, guidance  
65 driven by expert opinions suggested utilizing higher doses of anticoagulation.<sup>1</sup> However, this  
66 recommendation lacks robust, supporting systematic studies. Thus, we aimed to systematically  
67 review the literature and explore the pooled prevalence of VTE, PE, and DVT in critically ill  
68 COVID-19 patients. Additionally, to evaluate the yield of systematic VTE screening and its  
69 effect on the prevalence. Moreover, if data allow, to examine the odds of VTE in patients on  
70 prophylactic compared to therapeutic anticoagulation.

## 71 **Methods**

72 This review follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses  
73 (PRISMA) guidelines.<sup>5</sup> It is pre-registered at the International Prospective Register of Systematic  
74 Reviews (PROSPERO) (registration number: CRD42020185916).

75 **Eligibility criteria**

76 We limited our review to observational studies (cohort, cross-sectional, retrospective, or case  
77 series) estimating the proportion of VTE events in critically ill COVID-19 adult (>18 years)  
78 patients (admitted to ICU). To facilitate a timely review, we limited our inclusion to articles  
79 written in the English language only. We excluded studies where the proportion of VTE could  
80 not be ascertained, or if the population of interest is not ICU patients.

81 **Information sources and literature search**

82 For a timely review, we performed the search in PubMed, MEDLINE, and EMBASE. We used  
83 free text, emtree, and MeSH terms in our search. There was no language or date limitations  
84 implied in the search; The last date of the formal search was the 10<sup>th</sup> of July 2020; however, we  
85 performed a scoping search till July 25, 2020. Example of a utilized search strategy was  
86 (('venous thromboembolism' OR 'deep vein thrombosis' OR 'lung embolism' OR 'vein  
87 thrombosis'/exp/mj) AND [embase]/lim) AND (('covid 19' OR (coronavirus AND disease AND  
88 2019) OR (sars AND cov AND 2) OR 'covid 19'/exp/mj) AND [embase]/lim). We also  
89 performed relevant citations and reference searches.

90 **Screening and data extraction**

91 Two reviewers (MFHM) and (SFM) conducted the screening in two stages. The first stage was  
92 screening the retrieved articles' titles and abstracts independently. Secondly, the articles' full text  
93 was retrieved and assessed for inclusion. When disagreement occurred, a third reviewer (LOA)  
94 settled the disagreement guided by the protocol. We used pre-made excel sheets to collect  
95 relevant articles data. This included the last author name, publication date, study country, sample  
96 size, events number (DVT, PE, and VTE), baseline characteristics (median age, gender

97 frequency, average BMI, and other comorbidities), intubation frequency, thromboprophylaxis  
98 frequency, and follow-up duration.

### 99 **Study quality and risk of bias assessment**

100 We used a validated tool for assessing the risk of bias of prevalence studies. The tool was  
101 devised by Hoy et al. and is comprised of ten items summarizing four domains.<sup>6</sup> We additionally  
102 generated funnel plots to examine the risk of publication bias in our review.

### 103 **Statistical analysis**

104 A scoping review revealed heterogeneity of the method of VTE screening, reporting, and  
105 detection. Additionally, there were varying follow-ups given the nature of ICU admitted patients.  
106 Hence, neither the true incidence (different follow-up time and some patients may already have  
107 the event of interest before the study) nor the true prevalence (varying follow-up time and  
108 absence of unifying screening for all individuals at risk) could be accurately pooled. We instead  
109 decided a priori to pool a proportion of VTE with a 95% confidence interval. This proportion  
110 represents the number of patients with the event of interest divided by the study population at  
111 risk during the study regardless of their follow-up duration. We felt that this would be a proxy or  
112 an estimate of the prevalence. We used the validated method of double arcsine transformation to  
113 stabilize the variance and confine the confidence interval between 0-1.<sup>7</sup> We generated forest  
114 plots to display the results of the analysis. We used the Cochrane Q test and  $I^2$  to examine  
115 heterogeneity.  $I^2 > 60\%$  indicates significant heterogeneity. Regardless of the heterogeneity, we  
116 would use the random-effects model (REM) in our analysis. We used MetaXI software for  
117 statistical analysis (version 5.3 © EpiGear International Pty Ltd ABN 51 134 897 411 Sunrise  
118 Beach, Queensland, Australia, 2011–2016).

### 119 **Sub-group and sensitivity analyses**

120 We a priori decided to examine the proportion of DVT and PE. Additionally, we looked at the  
121 proportion of VTE in various populations (systematic screening vs. nonsystematic screening,  
122 therapeutic vs. prophylactic anticoagulant dose). Moreover, we performed a sensitivity analysis  
123 to reflect the relative constituent studies' impact on the consistency of the pooled proportion of  
124 the primary endpoint.

## 125 **Results:**

### 126 **Included studies and baseline characteristics**

127 Twenty-four studies describing a total of 2570 patients were included in our final analysis  
128 (Figure 1 shows the flow diagram).<sup>4,8-30</sup> The studies were heterogeneous in terms of VTE events  
129 identification and screening (Table 1). In ten studies, the screening for VTE was systematically  
130 done using lower and upper limb ultrasound (systematic screening was only for DVT and not  
131 PE). Fourteen studies evaluated for the presence of VTE based on clinical suspicion and further  
132 confirmation by imaging (nonsystematic). Twenty-two studies reported the proportion of DVTs,  
133 and seventeen studies reported the proportion of pulmonary embolism events. Out of the ten  
134 studies where systematic screening was adopted, the screening was incomplete in one. In all  
135 studies but one,<sup>26</sup> most patients were on thromboprophylaxis with varying doses.

### 136 **The proportion of VTE events**

137 The overall pooled proportion of VTE from 24 studies examining a total of 2570 was 0.31 (95%  
138 CI 0.24, 0.39 I<sup>2</sup> 94% Q 383) with significant heterogeneity (Figure 2). The funnel plot showed  
139 significant asymmetry suggestive of possible publication bias (Supplementary S 1). The  
140 sensitivity analysis did not affect the final point estimate significantly (Supplementary S 2).

### 141 **The proportion of VTE utilizing systematic screening**

142 Ten studies examining 478 patients using systematic screening, revealed a higher VTE  
143 proportion of 0.48 (95% CI 0.33, 0.63  $I^2$  91% Q 109) with significant heterogeneity (Figure 3).  
144 The funnel plot suggested a publication bias (Supplementary S3). The exclusion of Cui et al.'s  
145 study that did not utilize thromboprophylaxis resulted in a higher proportion of VTE events of  
146 0.51. Additional sensitivity analyses revealed a lower VTE proportion with the exclusion of Ren  
147 et al.'s data (0.43); this proportion increased with the exclusion of Criel et al.'s study (0.52)  
148 (Supplementary S4). All the studies evaluated systematically for the presence of DVT events  
149 only (PE was not a primary aim). Hence, this pooled proportion represents the proportion of  
150 DVT events and may underestimate the overall VTE proportion.

#### 151 **The proportion of VTE utilizing nonsystematic screening**

152 In most studies utilizing nonsystematic screening, the authors addressed the high threshold for  
153 screening and imaging due to infection control implications. They stated that this might have  
154 underestimated the true prevalence. The analysis of fourteen studies examining 2085 patients  
155 revealed a pooled proportion of VTE of 0.20 (95% CI 0.15, 0.26  $I^2$  87% Q 98.4) (Figure 4). The  
156 funnel plot suggested a publication bias (Supplementary S 5). On sensitivity analysis, the final  
157 point estimate did not significantly change with the ordered exclusion of the constituent studies  
158 (Supplementary S 6).

#### 159 **The proportion of DVT events**

160 The overall pooled proportion of DVT from 22 studies examining a total of 2401 was 0.23 (95%  
161 CI 0.14, 0.32  $I^2$  96% Q 531) with significant heterogeneity (Figure 5). The funnel plot suggested  
162 a publication bias (S7). While the sensitivity analysis suggested a consistency of the final point  
163 estimate with ordered-single-study exclusion (Supplementary S8). The pooled proportion of

164 DVT from studies utilizing nonsystematic screening was 0.08 (95% CI 0.04, 0.12  $I^2$  87% Q 85)  
165 (Supplementary S9).

### 166 **The proportion of PE events**

167 Pulmonary embolism was not screened systematically. The analysis of 2096 patients (17 studies)  
168 revealed a pooled proportion of 0.14 (95% CI 0.09, 0.20  $I^2$  90% Q 159) (Figure 6). The funnel  
169 plot revealed a major asymmetry suggestive of publication bias (Supplementary S 10).  
170 Sensitivity analysis showed consistency of the results upon single-study-ordered exclusion.

### 171 **Thromboprophylaxis strategy**

172 Six studies reported the number of VTE events in patients receiving prophylactic anticoagulation  
173 (479 patients) compared to therapeutic dosages (83 patients). The dosages and definitions varied  
174 across these studies. In one study (pre- and post-intervention), a higher prophylactic dosage of  
175 nadroparin with adjustment guided by factor X-a activity (labeled as semi-therapeutic) was  
176 compared with standard prophylactic dose.<sup>4,14,21</sup> For synthesis, we considered this adjusted dosage  
177 therapeutic and analyzed it in the corresponding arm (due to the paucity of studies). The VTE  
178 odds ratio was increased in the prophylactic anticoagulation group with uncertainty in the final  
179 point estimate OR 2.34 (95% CI 0.77, 7.14  $I^2$  53% Q 10). Three studies utilized systematic  
180 screening, hence, they provided a better estimate of the true VTE prevalence.<sup>21</sup> We analyzed  
181 these studies separately, and the results showed significantly increased odds of VTE events with  
182 prophylactic dosing OR 5.45 (95% CI 1.90, 15.57  $I^2$  0% Q 1.2), and there was no evidence of  
183 heterogeneity (Figure 7).

### 184 **Quality assessment and risk of bias assessment**



185 Most of the constituent studies had moderate or unclear risk of bias (Table 2). Although the  
186 number of included studies is adequate, the funnel plot suggested publication bias (Its value is  
187 limited in assessing prevalence studies publication bias). There was also reporting bias, as the  
188 reporting of distal DVT, PE, and VTE, method of diagnosis, dosing of chemoprophylaxis varied  
189 across studies.

## 190 **Discussion**

191 Our meta-analysis comprised of over 2500 patients and revealed a high VTE prevalence of 0.31  
192 (95% CI 0.24, 0.39) in critically ill COVID-19 patients. This prevalence increased to 0.48 (95%  
193 CI 0.33, 0.63) when systematic screening was utilized, meaning that almost one in two critical  
194 COVID-19 patients suffers from VTE. Furthermore, this heightened prevalence of VTE when  
195 systematic screening was used, did not include PE since it was not part of systematic screening.  
196 Hence, screening for PE systematically could have possibly further increased VTE prevalence.  
197 Even when nonsystematic screening was utilized, VTE prevalence remained high at 0.20 (95%  
198 CI 0.15, 0.26). Regarding PE and DVT prevalence, the overall prevalence of DVT (0.23) was  
199 higher than PE (0.14). This concurs with finding a high prevalence of undiagnosed DVT in  
200 autopsy evaluation of COVID-19 patients.<sup>31</sup> Additionally, it may argue against the earlier  
201 literature suggesting that PE prevalence was much higher than DVT, proposing that PE events  
202 can originate in the lung's vasculature in patients with SARS-CoV-2 infection.<sup>32</sup>

203 Our analysis revealed that approximately 40/100 additional DVTs are detected by systematic  
204 screening (0.48) compared to nonsystematic screening (0.08). This is likely due to the fact that  
205 asymptomatic DVT can be overlooked in nonsystematic screening. On the opposite side, PE is

206 more likely to be associated with easily detected signs (sudden deterioration, unexplained  
207 tachycardia or sudden changes in the ventilator settings) especially in the context of ICU.

208 A recent study by Zhang et al. evaluated the utility of bedside ultrasonography in the diagnosis  
209 of DVT. It revealed a significantly higher DVT prevalence in deceased patients compared with  
210 surviving COVID-19 critically ill patients [94% (33/35) Vs. 47% (22/46),  $p < 0.001$ ].<sup>33</sup>

211 Moreover, Wichmann et al. analyzed autopsies of 12 COVID-19 patients. They found that seven  
212 (58%) had undiagnosed VTE, while in four (33.3%), massive PE was the direct cause of death.<sup>31</sup>

213 Based on these data, we understand that the high mortality reported by many studies may  
214 actually be attributed to undiagnosed fatal VTE events. Consequently, studies with high  
215 mortality will likely underestimate the true VTE prevalence when deceased patients are excluded  
216 from screening. We additionally understand the impact of prevention and early identification on  
217 patient's morbidity and mortality.

218 Tang et al. showed that prophylactic dosing of heparin in high-risk COVID-19 patients is  
219 associated with significantly lower mortality.<sup>34</sup> This led the International Society on Thrombosis  
220 and Haemostasis (ISTH) amongst other societies to recommend a prophylactic dosage of  
221 pharmacological anticoagulants (LMWH or fondaparinux) for all hospitalized COVID-19  
222 patients<sup>35</sup>. However, it seemed that prophylactic anticoagulation is not sufficient for severe  
223 COVID-19 patients. This was concluded in a study by Llitjos and colleagues where they found a  
224 higher prevalence of VTE in patients on a prophylactic dose of anticoagulation (100%)  
225 compared to therapeutic anticoagulation (56%).<sup>36</sup> More recently, Stessel et al. attempted the first  
226 quasi-experimental trial (pre- and post-intervention) comparing the mortality and incidence of  
227 VTE between conventional prophylaxis (once-daily nadroparin calcium 2850 IU) compared to  
228 an individualized semi therapeutic, prophylactic dosage guided by factor Xa activity (semi-

229 therapeutic dosing). Both mortality (3.8% vs. 39.1%, P<0.001) and VTE (15.3% vs. 41.3%,  
230 P=0.03) were significantly lower in the aggressive thromboprophylaxis group.<sup>21</sup> Emerging  
231 evidence showed that even in COVID-19 patients receiving therapeutic anticoagulation, there is  
232 a high incidence of heparin resistance, and sub-optimal peak in anti-Xa levels.<sup>37,38</sup> This may  
233 explain, in part, the high rate of VTE in patients on usual prophylactic doses and, even in patients  
234 on therapeutic dosing (although relatively at a lower rate).

235 Our review also aimed to address the uncertainty of using higher vs. standard prophylactic doses.  
236 When we limited our analysis to studies that only used systematic screening, and thus reduce the  
237 chances of missing fatal VTE events, we found that prophylactic dosing was associated with  
238 increased odds of VTE compared to therapeutic dosing (one study was counted in the therapeutic  
239 side although it used subtherapeutic dosing, due to limited studies).<sup>21</sup> The results were  
240 homogenous. The reader should consider that the odds of VTE in the therapeutic arm were lower  
241 even in the likely event that those patients may have had VTE predisposing conditions, for which  
242 they were initiated on this therapeutic dosing (except Stessel et al.'s study, which was  
243 protocolized). This small unadjusted comparison suggests a value for a higher dosing or  
244 therapeutic chemoprophylaxis. Nonetheless, this will be confirmed by a number of ongoing trials  
245 aiming to address the efficacy and safety of various chemoprophylactic dosages (prophylactic,  
246 intermediates, weight-adjusted, or therapeutic); examples of such trials are IMPROVE  
247 ([Http://www.clinicaltrials.gov](http://www.clinicaltrials.gov). NCT04367831), COVI-DOSE ([Http://www.clinicaltrials.gov](http://www.clinicaltrials.gov).  
248 NCT04373707), and Hep-COVID (<https://www.clinicaltrials.gov>. NCT04401293). The safety of  
249 intensive thromboprophylaxis was not addressed in our review due to data paucity. Nonetheless,  
250 two recent observational studies suggested that this intensive thromboprophylaxis is safe in terms  
251 of inducing major bleeding events.<sup>39,40</sup> Thus, we believe that the intensive thromboprophylaxis

252 protocol suggested by Stessel et al. is a valid chemoprophylaxis regimen until further data from  
253 ongoing RCTs becomes available.<sup>21</sup>

254 Limitations of our review are the heterogeneity in the pooled prevalence in the constituent  
255 studies. This is likely due to varying detection methods (systematic vs. nonsystematic, imaging  
256 modalities used, timing, etc.), screening threshold (many studies reported that the threshold was  
257 high due to infection control concerns), varying severity of illness, prophylaxis strategies, and  
258 dosage, missing VTE in deceased patients of fatal VTE events, varying and insufficient follow-  
259 ups. Additionally, the inability to provide a mortality comparison between VTE group and non-  
260 VTE group due to data paucity (we contacted the primary authors; however, we could not get the  
261 data necessary for its computation), limited conclusion provided by the comparison of VTE in  
262 the therapeutic vs. prophylactic anticoagulation groups (absence of adjustment, varying doses  
263 between studies). Moreover, the retrospective nature of the included studies, inability to  
264 accurately compute the prevalence of PE (absence of systematic PE screening), and absence of  
265 autopsies to ascertain causes of death, adds to the limitations of our review.

266 Notwithstanding this, there are many strengths to our review that are worthy of mention. This is  
267 the most extensive review examining the prevalence of VTE exclusively in critically ill patients.  
268 Additionally, the review examines VTE prevalence based on the utilized screening method  
269 providing the readers with a better estimate of VTE prevalence. We also pooled a proportion that  
270 reflects the prevalence; nonetheless, we acknowledged its limited accuracy. Finally, we believe  
271 that the results of the limited comparison between lower and higher dosing of chemoprophylaxis  
272 will help inform therapeutic decisions until further data from RCTs becomes available.

273 Future research direction should evaluate the utility of systematic screening and early therapeutic  
274 anticoagulation dosage on outcomes (VTE progression, ICU stay, and mortality). The utility of  
275 systematic screening with US at regular intervals to ascertain the exact prevalence of VTE is  
276 needed. In these studies, patients with distal DVT should be temporally followed and compared  
277 to a non- DVT cohort, to determine the incidence of proximal DVT, PE, and mortality events.  
278 This will ascertain the exact need for therapy in these patients.

279 In conclusion, our review of critically ill COVID-19 patients revealed a high prevalence of VTE  
280 events. This prevalence is higher when systematic screening is utilized. Our review concluded a  
281 potential for higher prophylactic or therapeutic dosages in reducing VTE burden. Data from  
282 ongoing RCTs are awaited to further confirm the findings of our review.

### 283 **Declarations**

### 284 **Funding**

285 No funding sources.

### 286 **Conflict of Interest**

287 None declared by the authors relevant to this article.

### 288 **Availability of data**

289 Data are available upon request from the corresponding author.

### 290 **Author's contribution**

291 MFHM conceived the idea of the review and formed the team. MFHM conducted the initial  
292 search, and with SFM conducted the screening. MFHM, KMS, SDA, SFM, SII, MSN and LOA  
293 extracted the data. MFHM performed the analysis. MFHM constructed the tables and figures and  
294 wrote the initial draft; the manuscript was then critically reviewed and revised by all the study  
295 authors. The final version was approved by all authors for publication.

### 296 **Ethics approval**

297 Formal ethical approval was not needed for our review since it is a synthesis of already available  
298 data.

### 299 **Consent to participate**

300 Not applicable

### 301 **Consent for publication**

302 All authors approved the final version of the review for publication

### 303 **Acknowledgment**

304 We acknowledge the editor and the reviewers for the timely review and constructive feedback.

305

306

### 307 **References**

- 308 1. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications  
309 in critically ill ICU patients with COVID-19. *Thromb. Res.* 2020;
- 310 2. McFadyen JD, Stevens H, Peter K. The Emerging Threat of (Micro)Thrombosis in  
311 COVID-19 and Its Therapeutic Implications. *Circ. Res.* 2020;127:571–587.
- 312 3. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management  
313 of coagulopathy in COVID-19. *J. Thromb. Haemost.* 2020;18(5):1023–1026.
- 314 4. Llitjos JF, Chochois C, Monsallier JM, Ramakers M, Auvray M, Merouani K, LM. High  
315 incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients.
- 316 5. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic  
317 reviews and meta-analyses: The PRISMA statement. *BMJ.* 2009;339(7716):332–336.
- 318 6. Hoy D, Brooks P, Woolf A, et al. Assessing risk of bias in prevalence studies:

- 319 Modification of an existing tool and evidence of interrater agreement. *J. Clin. Epidemiol.*  
320 2012;65(9):934–939.
- 321 7. Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. *J.*  
322 *Epidemiol. Community Health.* 2013;67(11):974–978.
- 323 8. Al-Samkari H Dzik WH, Carlson JC, Fogerty AE, Waheed A, Goodarzi K, Bendapudi P,  
324 Bornikova L, Gupta S, Leaf D, Kuter DJ, Rosovsky RP. KLRS. COVID and Coagulation:  
325 Bleeding and Thrombotic Manifestations of SARS-CoV2 Infection.
- 326 9. Hippensteel JA Jolley SE. BEL. Prevalence of venous thromboembolism in critically ill  
327 patients with COVID-19.
- 328 10. F.A. K, M.J.H.A. K, N.J.M. van der M, et al. Confirmation of the high cumulative  
329 incidence of thrombotic complications in critically ill ICU patients with COVID-19: An  
330 updated analysis. *Thromb. Res.* 2020;
- 331 11. Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic  
332 complications in COVID-19 patients admitted to an academic hospital in Milan, Italy.  
333 *Thromb. Res.* 2020;191:9–14.
- 334 12. A. L, J. L, S. M-B, et al. Venous Thromboembolism in Critically Ill Patients with Covid-  
335 19: Results of a Screening Study for Deep Vein Thrombosis. *Res. Pr. Thromb. Haemost.*  
336 2020;
- 337 13. Maatman TK Feizpour C, Douglas A 2nd, McGuire SP, Kinnaman G, Hartwell JL,  
338 Maatman BT, Kreutz RP, Kapoor R, Rahman O, Zyromski NJ, Meagher AD. JF. Routine  
339 Venous Thromboembolism Prophylaxis May Be Inadequate in the Hypercoagulable State

- 340 of Severe Coronavirus Disease 2019.
- 341 14. Middeldorp S van Haaps TF, Foppen M, Vlaar AP, Müller MCA, Bouman CCS, Beenen  
342 LFM, Kootte RS, Heijmans J, Smits LP, Bonta PI, van Es N. CM. Incidence of venous  
343 thromboembolism in hospitalized patients with COVID-19.
- 344 15. Moll M, Zon RL, Sylvester KW, et al. Venous Thromboembolism in COVID-19 ICU  
345 Patients. *Chest*. 2020;0(0):
- 346 16. Nahum J Daviaud F, Echegut P, Fichet J, Maillet JM, Thierry S. M-BT. Venous  
347 Thrombosis Among Critically Ill Patients With Coronavirus Disease 2019 (COVID-19).
- 348 17. Pineton de Chambrun M Miyara M, Amoura Z, Martin-Toutain I, Mathian A, Hekimian  
349 G, Combes A. FC. High Frequency of Antiphospholipid Antibodies in Critically-ill  
350 COVID-19 Patients: a Link with Hypercoagulability?
- 351 18. Poissy J Caplan M, Parmentier E, Duburcq T, Lassalle F, Jeanpierre E, Rauch A,  
352 Labreuche J, Susen S GJ, group. LICUHC-19. Pulmonary Embolism in COVID-19  
353 Patients: Awareness of an Increased Prevalence.
- 354 19. Beun R Sikma M, Westerink J, Huisman A. KN. Thromboembolic events and apparent  
355 heparin resistance in patients infected with SARS-CoV-2.
- 356 20. Ren B, Yan F, Deng Z, et al. Extremely High Incidence of Lower Extremity Deep Venous  
357 Thrombosis in 48 Patients with Severe COVID-19 in Wuhan. *Circulation*.  
358 2020;142(2):181–183.
- 359 21. Stessel B, Vanvuchelen C, Bruckers L, et al. Impact of implementation of an  
360 individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19:



- 361 A longitudinal controlled before-after study. *Thromb. Res.* 2020;194:209–215.
- 362 22. Thomas W, Varley J, Johnston A, et al. Thrombotic complications of patients admitted to  
363 intensive care with COVID-19 at a teaching hospital in the United Kingdom. *Thromb.*  
364 *Res.* 2020;0(0):
- 365 23. Ren B Deng Z, Zhang S, Xiao L, Wu M, Cai L. YF. Extremely High Incidence of Lower  
366 Extremity Deep Venous Thrombosis in 48 Patients with Severe COVID-19 in Wuhan.
- 367 24. Bilaloglu S, Aphinyanaphongs Y, Jones S, et al. Thrombosis in Hospitalized Patients with  
368 COVID-19 in a New York City Health System. *JAMA - J. Am. Med. Assoc.* 2020;
- 369 25. Criel M Jaeken J, Van Kerrebroeck M, Lefere I, Meylaerts L, Mesotten D, Vander  
370 Laenen M, Fizez T, Thomeer M, David R. FM. Venous thromboembolism in SARS-CoV-  
371 2 patients: only a problem in ventilated ICU patients, or is there more to it?
- 372 26. S. C, S. C, X. L, S. L, F. W. Prevalence of venous thromboembolism in patients with  
373 severe novel coronavirus pneumonia. *J. Thromb. Haemost.* 2020;
- 374 27. Desborough MJR Griffiths A, Retter A, Breen KA, Hunt BJ. DAJ. Image-proven  
375 thromboembolism in patients with severe COVID-19 in a tertiary critical care unit in the  
376 United Kingdom.
- 377 28. Fraissé M Pajot O, Mentec H, Plantefève G, Contou D. LE. Thrombotic and hemorrhagic  
378 events in critically ill COVID-19 patients: a French monocenter retrospective study.
- 379 29. Grandmaison G, Andrey A, Périard D, et al. Systematic Screening for Venous  
380 Thromboembolic Events in COVID-19 Pneumonia. *TH Open.* 2020;04(02):e113–e115.
- 381 30. Helms J Severac F, Leonard-Lorant I, Ohana M, Delabranche X, Merdji H, Clere-Jehl R,

- 382 Schenck M, Fagot Gandet F, Fafi-Kremer S, Castelain V, Schneider F, Grunebaum L,  
383 Anglés-Cano E, Sattler L, Mertes PM, Meziani F TC, Sepsis). R in. High risk of  
384 thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective  
385 cohort study.
- 386 31. Wichmann D, Sperhake J-P, Lütgehetmann M, et al. Autopsy Findings and Venous  
387 Thromboembolism in Patients With COVID-19. *Ann. Intern. Med.* 2020;
- 388 32. Spyropoulos AC, Weitz JI. Hospitalized COVID-19 Patients and Venous  
389 Thromboembolism: A Perfect Storm. *Circulation.* 2020;142(2):129–132.
- 390 33. Zhang P, Qu Y, Tu J, et al. Applicability of bedside ultrasonography for the diagnosis of  
391 deep venous thrombosis in patients with <scp>COVID</scp> □19 and treatment with low  
392 molecular weight heparin. *J. Clin. Ultrasound.* 2020;jcu.22898.
- 393 34. Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased  
394 mortality in severe coronavirus disease 2019 patients with coagulopathy. *J. Thromb.*  
395 *Haemost.* 2020;18(5):.
- 396 35. Marietta M, Ageno W, Artoni A, et al. COVID-19 and haemostasis: A position paper from  
397 Italian Society on Thrombosis and Haemostasis (SISET). *Blood Transfus.*  
398 2020;18(3):167–169.
- 399 36. J.-F. L, M. L, C. C, et al. High incidence of venous thromboembolic events in  
400 anticoagulated severe COVID-19 patients. *J. Thromb. Haemost.* 2020;
- 401 37. Beun R, Kusadasi N, Sikma M, Westerink J, Huisman A. Thromboembolic events and  
402 apparent heparin resistance in patients infected with SARS-CoV-2. *Int. J. Lab. Hematol.*

403 2020;42(S1):19–20.

404 38. White D, MacDonald S, Bull T, et al. Heparin resistance in COVID-19 patients in the  
405 intensive care unit. *J. Thromb. Thrombolysis*. 2020;50(2):287–291.

406 39. Mattioli M, Benfaremo D, Mancini M, et al. Safety of intermediate dose of low molecular  
407 weight heparin in COVID-19 patients. *J. Thromb. Thrombolysis*. 2020;1–7.

408 40. Kessler C, Stricker H, Demundo D, et al. Bleeding prevalence in COVID-19 patients  
409 receiving intensive antithrombotic prophylaxis. *J. Thromb. Thrombolysis*. 2020;1–4.

410

411

## 412 **Tables**

413 **Table 1:** Summary of included studies

414

415

416

417

418

419

Study (Location)	Study Design	Study Duration in days	Total Number	Age, mean or median (Males percentage %)	Intubated %	D-dimers (Mean or median)	Body mass Index (Mean or median)	Pharmacologic prophylaxis %	Screening method	VTE proportion % (numbers)	Mortality %
Al-sankari 2020 (United States) <sup>8</sup>	Retrospective analysis	36 d (March-April 2020)	-	65 (males 64.7%)	-	-	-	98.6% (12.5% intermediate or full anticoagulation)	Clinical suspicion	10.4% (15/144)	18.8% (27/144)
Beun 2020 (Netherlands) <sup>19</sup>	Retrospective analysis	24 days (March-April 2020)	75	-	-	-	-	.	Clinical suspicion	30.6% (23/75)	-
Bilaloglu 2020 (USA) <sup>24</sup>	Retrospective analysis	48 d (March-April 2020)	829	-	-	-	-	Most patients (percentage not specified)	Clinical suspicion	13.6 % (113/829)	54.4% (451/829)
Criel 2020 (Belgium) <sup>25</sup>	Retrospective analysis	24 d (April 2020)	30	64.5 (males 67%)	70%	1400 ng/mL	30.3	100% (intermediate prophylactic dose)	Systematic screening (Doppler US of Upper and Lower Limbs)	13.3% (4/30)	13.3% (4/30)
Cui 2020 (China) <sup>26</sup>	Retrospective analysis	53 d (Jan-March 2020)	81	59.9 (males 46%)	-	5200 ng/mL	-	0%	Systematic screening (lower limb doppler US)	24.6% (20/81)	10% (8/81)
Desborough 2020 (United Kingdom) <sup>27</sup>	Retrospective analysis	31 d (March 2020)	66	59 (males 73%)	79%	1200 ng/mL	28	100% (83% prophylactic, 17% therapeutic)	Clinical suspicion	16.6% (11/66)	30.3% (20/66)
Fraissé 2020 (France) <sup>28</sup>	Retrospective analysis	-	92	61 (male 79%)	89%	2400ng/ml	30	100 % (47% prophylactic, 53% therapeutic)	Clinical suspicion	33.6% (31/92)	-
Grandmaison 2020 (Switzerland)	Retrospective analysis	-	29	66 (male 64.7%)	-	8760 ng/mL	27	93% (96% prophylactic, 4% therapeutic)	Systematic screening (Doppler US)	58.6% (17/29)	-

<sup>29</sup>									of upper and lower limbs)		
Helms 2020 (France) <sup>30</sup>	Retrospective analysis	29 d (March 2020)	150	63 (males 81%)	100%	2270 ng/ml	-	100% (70% prophylactic, 30% therapeutic)	Clinical suspicion	18.6% (28/150)	8.70% (13/150)
Hippensteel 2020 (United States) <sup>9</sup>	Retrospective analysis	28 days (March-April 2020)	91	55 (male 57%)	85%	1071 ng/ml	32.1	54.3% Therapeutic	Clinical suspicion	26.3% (24/91)	22% (22/91)
Klok 2020 (Netherlands) <sup>10</sup>	Retrospective analysis	47 d (March-April 2020)	184	64 (males 76%)	-	-	-	100% (90.8% prophylactic, 9.2% therapeutic)	Clinical suspicion	36.9% (68/184)	22% (41/184)
Llitjos 2020 (France) <sup>4</sup>	Retrospective analysis	24 d (March-April 2020)	26	68 (males 77%)	100%	1750ng/ml	30.2	100% (prophylactic 31%, therapeutic 69%)	Systematic screening (compression and doppler US)	69.2% (18/26)	12% (3/26)
Lodgiani 2020 (Italy) <sup>11</sup>	Retrospective analysis	58 d (February-April 2020)	48	61 (male 80.3%)	-	615 ng/ml	-	100% (40% weight adjusted or therapeutic)	Clinical suspicion	8.3% (4/48)	-
longchamp 2020 (Switzerland) <sup>12</sup>	Retrospective analysis	26 d (March-April 2020)	25	68 (males 64%)	92%	2071 ng/ml (953-3606)	27.5	100% (Prophylactic 23/25, Therapeutic 2/25)	Systematic screening (proximal lower extremity DVT)	32% (8/25)	20% (5/25)
Maatman 2020 (United States) <sup>13</sup>	Retrospective analysis	20 d (March 2020)	109	61(males 57%)	94%	84506 ng/ml	34.8 ± 11.8	100% (prophylactic 102/109, Therapeutic 7/109)	Clinical suspicion	28.4% (31/109)	25% (27/109)
Middeldorp 2020 (Netherlands) <sup>14</sup>	Retrospective analysis	42 d (March-April 2020)	75	62 (Males 58 %)	100%	2000 ng/ml	27	100%	Systematic screening (lower limb doppler every 5 days)	46.6 % (35/75)	.

Moll 2020 (United States) <sup>15</sup>	Retrospective analysis	38 d (March-April 2020)	102	64.61 (males 57.8%)	86.3%	3964 ng/mL	30.08	97.1% (89.8% prophylactic, 10.1% therapeutic)	Clinical suspicion	8.8% (9/102)	27.5% (28/102)
Nahum 2020 (France) <sup>16</sup>	case series	Mid-March-April 2020	34	62.2 (male 78%)	100%	27927 ng/mL	31.4	100% prophylactic anticoagulation	Systematic screening (lower limbs US for all patients)	79.4% (27/34)	Not mentioned
Pineton De Chambrun 2020 (France) <sup>17</sup>	Retrospective analysis	26 d (March-April 2020)	25	47.7 (males 68%)	-	Highly elevated (NS)	-	100% therapeutic	Clinical suspicion	24% (6/25)	-
Poissy 2020 (France) <sup>18</sup>	Retrospective analysis	34 d (February-March 2020)	107	57 (males 59%)	62.6%	-	30	100%	Clinical suspicion	22.4 % (24/107)	14% (15/107)
Ren 2020 (China)	Cross-sectional	3 days (Feb-March)	48	70 (males 54.2%)	37.5%	3480 ng/mL	.	97.9% prophylactic	Systematic screening (proximal and distal lower limbs compression US)	85.4% (41/48)	31.3% (15/48)
Stessel 2020 1 (Belgium) <sup>21</sup>	Quasi-experimental	18 d (March 2020)	46	69.5 (males 73.9%)	-	970 ng/mL	26.2	100% Prophylactic standard dose	Systematic screening	41.3% (19/46)	39.13 % (18/46)
Stessel 2020 2 (Belgium) <sup>21</sup>	Quasi-experimental	21 d (March-April 2020)	26	62 (males 57.3%)	-	2180 ng/mL	27	100 % Intensive prophylactic dose	Systematic screening (Doppler US and Compression US of the great veins in upper and lower limbs)	15.3% (4/26)	3.85% (1/26)
Thomas 2020 (United States)	Retrospective analysis	33 d (March-April 2020)	63	59 (male 69%)	83%	394 ng/ml	-	100% (prophylactic)	Clinical suspicion	9.5% (6/63)	8% (5/63)

Kingdom) <sup>22</sup>		April 2020)						dose)			
Zhang 2020 (China) <sup>23</sup>	Retrospective analysis	32 d (January February 2020)	65	-	-	-	-	-	Systematic screening (Lower limbs US doppler for DVT at proximal and distal levels)	66.1% (43/65)	-
(-)	Refers	to	data	unavailable	for	the	ICU	cohort			

**Table 2:** Table summarizing the risk of bias assessment



Study	1	2	3	4	5	6	7	8	9
Al-samkari 2020 <sup>8</sup>	?	+	+	-	-	-	-	-	-
Beun 2020 <sup>19</sup>	+	?	+	-	-	+	-	-	-
Bilaloglu 2020 <sup>24</sup>	+	+	+	?	-	+	-	-	-
Criel 2020 <sup>25</sup>	?	?	-	+	+	?	+	+	-
Cui 2020 <sup>26</sup>	?	?	-	?	+	?	+	+	-
Desborough 2020 <sup>27</sup>	+	+	+	+	-	+	-	-	-
Fraissé 2020 <sup>28</sup>	+	?	-	+	-	+	-	-	-
Grandmaison 2020 <sup>29</sup>	+	+	-	+	+	+	+	+	-
Helms 2020 <sup>30</sup>	+	+	-	+	-	+	-	-	-
Hippensteel 2020 <sup>9</sup>	+	+	-	+	-	+	-	-	-
Klok 2020 <sup>10</sup>	+	+	+	+	-	-	-	-	-
Llitjos 2020 <sup>4</sup>	+	+	-	+	+	+	+	+	-
Lodgiani 2020 <sup>11</sup>	+	+	+	+	-	+	-	-	-
longchamp 2020 <sup>12</sup>	?	-	-	-	-	?	+	-	-
Maatman 2020 <sup>13</sup>	+	+	-	+	-	+	-	-	-
Middeldorp 2020 <sup>14</sup>	+	+	+	+	+	+	+	-	-
Moll 2020 <sup>15</sup>	+	+	+	+	-	+	-	-	-
Nahum 2020 <sup>16</sup>	+	+	-	+	+	+	+	+	-
Pineton de Chambrun 2020 <sup>17</sup>	+	+	+	+	-	-	-	-	-
Poissy 2020 <sup>18</sup>	+	+	+	+	-	-	-	-	-
Ren 2020 <sup>20</sup>	+	+	+	+	+	+	+	+	-
Stessel 2020 1 <sup>21</sup>	+	+	+	+	?	+	+	+	-
Stessel 2020 2 <sup>21</sup>	+	+	+	+	+	+	+	+	-
Thomas 2020 <sup>22</sup>	+	+	-	-	-	+	-	-	-
Zhang 2020 <sup>23</sup>	?	+	+	-	?	+	?	+	-

 low risk;  
 high risk;  
 unclear risk assessment

(1) Was the study's target population a close representation of the national population

in relation to relevant variables, e.g. age, sex, occupation?; (2) Was the sampling frame a true or close representation of the target population?; (3) Was some form of random selection used to select the sample, OR, was a census undertaken; (4) Was the likelihood of non-response bias minimal?; (5) Were data collected directly from the subjects (as opposed to a proxy); (6) Was an acceptable case definition used in the study?; (7) Was the study instrument that measured the parameter of interest (e.g. prevalence of low back pain) shown to have reliability and

validity (if necessary)?; (8) Was the same mode of data collection used for all subjects?; (9) Were the numerator(s) and denominator r(s) for the parameter of interest appropriate

## Figure Captions

**Figure 1:** PRISMA flow diagram

**Figure 2:** Forest plot showing the overall pooled proportion of VTE events

**Figure 3:** Forest plot showing the pooled proportion of VTE events utilizing systematic screening methods


**Figure 4:** Forest plot showing the pooled proportion of VTE events utilizing non-systematic screening methods

**Figure 5:** Forest plot showing the overall pooled proportion of DVT

**Figure 6:** Forest plot showing the overall pooled proportion of PE

**Figure 7:** Forest plot showing the VTE event odds in the prophylactic anticoagulation group, compared to therapeutic dosing

Figure 1: PRISMA flow diagram



medRxiv preprint doi: <https://doi.org/10.1101/2020.08.24.20175745>; this version posted August 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit [www.prisma-statement.org](http://www.prisma-statement.org).

Figure 2: Forest plot showing the overall pooled proportion of VTE events






Figure 3: Forest plot showing the pooled proportion of VTE events utilizing systematic screening methods




medRxiv preprint doi: <https://doi.org/10.1101/2020.08.24.20175745>; this version posted August 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Figure 4: Forest plot showing the pooled proportion of VTE events utilizing non-systematic screening methods



medRxiv preprint doi: <https://doi.org/10.1101/2020.08.24.20175745>; this version posted August 25, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Figure 5: Forest plot showing the overall pooled proportion of DVT



medRxiv preprint doi: <https://doi.org/10.1101/2020.08.24.20175745>; this version posted August 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.



Figure 6: Forest plot showing the overall pooled proportion of PE




Figure 7: Forest plot showing the VTE event odds in the prophylactic anticoagulation group, compared to therapeutic dosing

